Literature DB >> 19890057

RREB-1 is a transcriptional repressor of HLA-G.

Sébastien Flajollet1, Isabelle Poras, Edgardo D Carosella, Philippe Moreau.   

Abstract

The nonclassical HLA-G is a molecule specifically involved in immune tolerance with highly restricted tissue distribution in healthy conditions. Yet it is overexpressed in numerous tumors and in allografts with better acceptance. Major mechanisms involved in regulation of HLA-G transcription are still poorly described. Thus, to characterize these mechanisms we have developed a specific proteomic approach to identify proteins that bind differentially to the HLA-G gene promoter by promoter pull-down assay followed by spectrometry mass analysis. Among specific binding factors, we focused on RREB-1, a ras-responsive element binding protein 1. We demonstrated that RREB-1 represses HLA-G transcriptional activity and binds three ras response elements within the HLA-G promoter. RREB-1 protein, specifically in HLA-G-negative cells, interacts with subunits of CtBP complex implicated in chromatin remodeling. This demonstration is the first of a repressor factor of HLA-G transcriptional activity taking part in HLA-G repression by epigenetic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19890057     DOI: 10.4049/jimmunol.0902053

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  Frequency of HLA-G exon 8 polymorphisms and kidney allograft outcome in Iranian population.

Authors:  Mahdokht H Aghdaie; Negar Azarpira; Kurosh Kazemi; Bita Geramizadeh; Masumeh Darai; Seid Ali Malekhoseini
Journal:  Mol Biol Rep       Date:  2010-11-24       Impact factor: 2.316

2.  The Samd9L gene: transcriptional regulation and tissue-specific expression in mouse development.

Authors:  Qiujie Jiang; Benjamin Quaynor; Alex Sun; Qiaoli Li; Hirotaka Matsui; Hiroaki Honda; Toshiya Inaba; Eli Sprecher; Jouni Uitto
Journal:  J Invest Dermatol       Date:  2011-03-17       Impact factor: 8.551

3.  Evidence for changes in RREB-1, ZIP3, and Zinc in the early development of pancreatic adenocarcinoma.

Authors:  Leslie C Costello; Jing Zou; Mohamed Mokhtar Desouki; Renty B Franklin
Journal:  J Gastrointest Cancer       Date:  2012-12

4.  Decreased zinc and downregulation of ZIP3 zinc uptake transporter in the development of pancreatic adenocarcinoma.

Authors:  Leslie C Costello; Bernard A Levy; Mohamed M Desouki; Jing Zou; Omar Bagasra; Leslie A Johnson; Nader Hanna; Renty B Franklin
Journal:  Cancer Biol Ther       Date:  2011-08-15       Impact factor: 4.742

5.  RREB1 transcription factor splice variants in urologic cancer.

Authors:  Matthew D Nitz; Michael A Harding; Steven C Smith; Shibu Thomas; Dan Theodorescu
Journal:  Am J Pathol       Date:  2011-07       Impact factor: 4.307

6.  The Autoimmune Regulator (Aire) transactivates HLA-G gene expression in thymic epithelial cells.

Authors:  Breno Luiz Melo-Lima; Isabelle Poras; Geraldo Aleixo Passos; Edgardo D Carosella; Eduardo Antonio Donadi; Philippe Moreau
Journal:  Immunology       Date:  2019-08-19       Impact factor: 7.397

Review 7.  Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?

Authors:  Laurence Amiot; Soldano Ferrone; Hans Grosse-Wilde; Barbara Seliger
Journal:  Cell Mol Life Sci       Date:  2010-11-10       Impact factor: 9.261

8.  The cytotoxic role of RREB1, ZIP3 zinc transporter, and zinc in human pancreatic adenocarcinoma.

Authors:  Renty B Franklin; Jing Zou; Leslie C Costello
Journal:  Cancer Biol Ther       Date:  2014-07-22       Impact factor: 4.742

9.  CtBP and associated LSD1 are required for transcriptional activation by NeuroD1 in gastrointestinal endocrine cells.

Authors:  Subir K Ray; H Joyce Li; Eric Metzger; Roland Schüle; Andrew B Leiter
Journal:  Mol Cell Biol       Date:  2014-04-14       Impact factor: 4.272

10.  The transcription factor Rreb1 regulates epithelial architecture, invasiveness, and vasculogenesis in early mouse embryos.

Authors:  Sophie M Morgani; Jie Su; Jennifer Nichols; Joan Massagué; Anna-Katerina Hadjantonakis
Journal:  Elife       Date:  2021-04-30       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.